1[1]Kannel WB, Abbott RD, Savage DD, et al. Epidemiologic features of chronic atrial fibrillation: the Framingham study[J]. N Engl J Med, 1982, 306:1018～1022
2[2]Stewart S, Maclntyre K, Macleod MMC, et al. Trends in hospital activity, morbidity and case fatality related to atrial fibrillation in Scotland, 1986-1996[J]. Eur Heart J, 2001, 22(8): 693～701
3[3]Levy S, Maarek M, Coumel P, et al. Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. Circulation, 1999, 99: 3028-3035
4[4]Igarashi Y, Kasai H, Yamashita F, et al. Lipoprotein(a), left atrial appendage function and thromboembolic risk in patients chronic non-valvular atrial fibrillation[J]. Jpn Circ J, 2000, 64: 93～98
5[5]Petersen P. Thromboembolic complications in atrial fibrillation[J]. Stroke, 1990, 21: 4～13
6[6]Wolf PA, Abbott RD, Kannel WB, et al. Atrial fibrillation as an independent risk factor for stroke: the Framingham study[J]. Stroke, 1991, 22: 983～988
7[7]Hart RG,Benavent O,MeBride R,et al.Antithrombotic therapy to prevent stroke in patients with atrial fibrillation:a meta-analysis[J].Ann Intern Med,1999,131:492～501
8[8]Gage BF, Boechler M, Doggette AL, et al. Adverse outcomes and predictors of underuse of antithrombotic therapy in medicare beneficiaries with chronic atrial fibrillation[J]. Stroke, 2000, 31: 822～827
6Dyrda K,Piers SR, Van Huls van Taxis CF, et al.Influence of Steroid Therapy on the Incidence of Pericarditis and Atrial Fibrillation Following Percutaneous Epicardial Mapping and Ablation for Ventricular Tachyeardia[J].Circ Arrhythm Electrophysiol,2014,7 (4):671-676.
